{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:14:51Z","timestamp":1791756891081,"version":"4.3.4"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Forensic and Legal Medicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jflm.2023.102542","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:23:58Z","timestamp":1684754638000},"page":"102542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["The first drug-related death associated with xylazine use in the UK and Europe"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-7585","authenticated-orcid":false,"given":"Kirsten L.","family":"Rock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric","family":"Treble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-1402","authenticated-orcid":false,"given":"Caroline S.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jflm.2023.102542_bib1","series-title":"FDA Alerts Health Care Professionals of Risks to Patients Exposed to Xylazine in Illicit Drugs","author":"Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.jflm.2023.102542_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jflm.2023.102542_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","article-title":"Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature","volume":"240","author":"Ruiz-Col\u00f3n","year":"2014","journal-title":"Forensic Sci Int"},{"issue":"3","key":"10.1016\/j.jflm.2023.102542_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.drugalcdep.2008.03.005","article-title":"GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles","volume":"96","author":"Rodr\u00edguez","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.jflm.2023.102542_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-021-00546-9","article-title":"Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications","volume":"18","author":"Bowles","year":"2021","journal-title":"Harm Reduct J"},{"issue":"Suppl 2","key":"10.1016\/j.jflm.2023.102542_bib6","first-page":"S129","article-title":"Inherent dangers of using non-US Food and drug administration-approved substances of abuse","volume":"61","author":"White","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jflm.2023.102542_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bcp.14135","article-title":"A deadly trend in fentanyl fatalities (England, 1998-2017)","volume":"86","author":"Claridge","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jflm.2023.102542_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1747-597X-6-7","article-title":"Xylazine (veterinary sedative) use in Puerto Rico","volume":"6","author":"Torruella","year":"2011","journal-title":"Subst Abuse Treat Prev Pol"},{"key":"10.1016\/j.jflm.2023.102542_bib9","series-title":"Drug Checking Quarterly Report (Q3 2022)","year":"2022"},{"key":"10.1016\/j.jflm.2023.102542_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/injuryprev-2020-043968","article-title":"Increasing presence of xylazine in heroin and\/or fentanyl deaths, Philadelphia, Pennsylvania, 2010\u20132019","volume":"27","author":"Johnson","year":"2021","journal-title":"Inj Prev"},{"issue":"3","key":"10.1016\/j.jflm.2023.102542_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","article-title":"The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico","volume":"89","author":"Reyes","year":"2012","journal-title":"J Urban Health"},{"issue":"8","key":"10.1016\/j.jflm.2023.102542_bib12","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1111\/bcp.15352","article-title":"Fatalities associated with gabapentinoids in England (2004-2020)","volume":"88","author":"Kalk","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jflm.2023.102542_bib13","series-title":"National Drug Threat Assessment","year":"2020"},{"key":"10.1016\/j.jflm.2023.102542_bib14","series-title":"National Strategic Assessment of Serious and Organised Crime 2021","year":"2021"}],"container-title":["Journal of Forensic and Legal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1752928X23000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1752928X23000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:18:10Z","timestamp":1761697090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1752928X23000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":14,"alternative-id":["S1752928X23000604"],"URL":"https:\/\/doi.org\/10.1016\/j.jflm.2023.102542","relation":{},"ISSN":["1752-928X"],"issn-type":[{"value":"1752-928X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The first drug-related death associated with xylazine use in the UK and Europe","name":"articletitle","label":"Article Title"},{"value":"Journal of Forensic and Legal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jflm.2023.102542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102542"}}